Peptides for Wound Healing: BPC-157, TB-500, KPV, and GHK-Cu

This guide is deliberately honest about evidence quality. Wound-healing peptides are marketed with confidence that the science does not always support. Below, each peptide is labeled by whether its wound-healing evidence is human, preclinical (animal), or anecdotal, so you can make a decision with clear eyes. None of these is a replacement for surgical wound care.

1. The wound healing cascade and where peptides fit

Wound healing is not one event. It is an ordered, overlapping sequence of four phases, and the peptides discussed here each intervene at a different point:

1. Hemostasis. Within minutes of injury the body clots to stop bleeding. No peptide is meaningfully involved here.
2. Inflammation. Immune cells clear debris and pathogens. This phase is necessary, but when it runs too long it stalls healing. KPV and TB-500 act here, dampening excess inflammatory signaling.
3. Proliferation. New blood vessels (angiogenesis), new tissue (granulation), and cell migration rebuild the wound bed. BPC-157 and TB-500 are most active in this phase.
4. Remodeling. Collagen is laid down, cross-linked, and reorganized over weeks to months, determining final tissue strength and scar quality. GHK-Cu is a remodeling-phase agent.

The practical takeaway: because these peptides act in different phases, they are usually combined rather than used alone. A stack that covers inflammation, proliferation, and remodeling addresses more of the cascade than any single molecule. That is the logic behind the multi-peptide healing vials a 503A pharmacy can compound.

2. BPC-157: angiogenesis and tissue repair

BPC-157 (Body Protection Compound, a 15-amino acid gastric pentadecapeptide) is the best-known recovery peptide. Its proposed role in wound healing is in the proliferation phase: promoting the new blood vessels and growth-factor signaling that rebuild damaged tissue.

Mechanism. According to PubMed, rodent studies show BPC-157 modulates angiogenesis by upregulating vascular endothelial growth factor (VEGF) expression during muscle and tendon healing, and it improves early functional recovery in transected Achilles tendon models through combined anti-inflammatory action and new blood vessel formation (Brcic et al., no direct human equivalent; Krivic et al., DOI). In plain terms, in animals it helps the wound bed re-vascularize and calm down faster.

Evidence tier: preclinical. This is the part the marketing usually skips. The compelling BPC-157 wound data is in rodents. A PubMed search for completed human BPC-157 clinical trials returns nothing. The bodybuilding and sports-medicine anecdotal record is large and unusually consistent (faster return from soft-tissue injury), but anecdote is not a trial. Use BPC-157 with informed expectations.

Form and dosing. RxPepsDirect's prescribers can request BPC-157 as an injectable vial (5mL, 3mg/mL, 15mg total) at a typical starting dose of 20 units (0.6mg) subcutaneous or intramuscular, daily Monday through Friday. An oral capsule form (500mcg) exists and is most relevant for gut-lining healing rather than external wounds. Medication is billed by Optimal Balance Pharmacy; the standalone injectable lists at $80 for the 15mg vial.

→ Full mechanism, dosing, and the evidence limits: BPC-157 protocol guide | Sourcing and legality: where and how to buy BPC-157

3. TB-500: cell migration and inflammation control

TB-500 is a synthetic version of the active region (the LKKTETQ sequence) of thymosin beta-4, a naturally occurring actin-binding peptide. Where BPC-157 acts locally, TB-500 is described as a more systemic agent: it circulates and supports cell migration to sites of damage throughout the body.

Mechanism. According to PubMed, the LKKTETQ segment within thymosin beta-4 is the active site responsible for actin binding, cell migration, and wound healing; TB-500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissue, keratinocyte migration, collagen deposition, and reduced inflammation (Ho et al., DOI). Those properties map directly onto the inflammation and proliferation phases of the wound cascade.

Evidence tier: preclinical. Like BPC-157, the human RCT base for TB-500 in wound healing is thin. The mechanism is well characterized at the molecular level, but dermal and soft-tissue benefits in people are extrapolated rather than proven. That source above is, notably, a doping-control method paper, which is a reminder that much of the TB-500 literature comes from sports-testing and veterinary contexts, not human wound-healing trials.

How it is offered. TB-500 is not prescribed as a standalone product through RxPepsDirect. It is available only inside combination vials, most commonly the Wolverine Stack (BPC-157 and TB-500 in one vial). The Wolverine Stack lists at $100 for a 15mg + 15mg vial, dosed at 20 units (0.6mg BPC-157 + 0.6mg TB-500) daily Monday through Friday.

→ The combined BPC-157 and TB-500 protocol, mechanism, and evidence: the Wolverine Stack explained

4. KPV: anti-inflammatory wound healing

KPV (lysine-proline-valine) is a tripeptide derived from the C-terminus of alpha-MSH (alpha-melanocyte-stimulating hormone). Its contribution to wound healing is not tissue building but inflammation control: a wound that is stuck in a prolonged inflammatory phase will not progress to proliferation and remodeling.

Mechanism. According to PubMed, KPV showed significant anti-inflammatory effects in two murine models of colitis, leading to earlier recovery, reduced inflammatory infiltrate, and lower myeloperoxidase activity, partly independent of the melanocortin-1 receptor (Kannengiesser et al., DOI). A later study found targeted oral KPV delivery accelerated mucosal healing and downregulated TNF-alpha in a colitis model (Xiao et al., DOI). KPV suppresses NF-kB inflammatory signaling, which is the pathway that keeps a wound inflamed.

Evidence tier: preclinical, and indirect. Note carefully: the strongest KPV evidence is in intestinal inflammation and mucosal healing, not external skin or surgical wounds. The anti-inflammatory mechanism is real and well documented in animals, but applying it to a skin wound is an extrapolation. KPV's clearest fit is wounds with a heavy inflammatory or autoimmune component.

How it is offered. Like TB-500, KPV is not a standalone product. It appears in combination vials: the triple stack BPC-157/TB-500/KPV ($120 for a 15mg + 15mg + 15mg vial) and the four-peptide KLOW vial (BPC-157, TB-500, GHK-Cu, KPV). Both are dosed at 20 units daily Monday through Friday.

5. GHK-Cu: collagen synthesis (topical and injectable)

GHK-Cu is the copper-binding tripeptide glycyl-L-histidyl-L-lysine complexed with copper. It is naturally present in human plasma, declines with age, and is the remodeling-phase peptide of this group. Of the four, it has the strongest human evidence.

Mechanism. According to PubMed, GHK and GHK-Cu activate a wide range of tissue-remodeling processes: chemoattraction of repair cells (macrophages, mast cells, capillary cells), anti-inflammatory and antioxidant actions, and increased synthesis of collagen, elastin, VEGF, and other growth factors. Controlled studies on aged skin showed it tightens skin and improves elasticity, firmness, fine lines, and photodamage, and the peptide has stimulated wound healing across numerous models including in humans (Pickart, DOI). Preclinical work also shows anti-inflammatory and antifibrotic effects in a pulmonary fibrosis model (Ma et al., DOI).

Evidence tier: human (for skin). This is the one peptide here with a documented human cosmetic and skin-remodeling track record. Evidence for severe or chronic wounds in humans is still thinner, so it is best framed as a skin-quality and post-procedure remodeling agent rather than a treatment for deep or chronic wounds.

Form and dosing. GHK-Cu is available as an injectable vial (5mL, 10mg/mL, 50mg total) at a typical 20-unit (2mg) dose, and it can also be used topically, which makes it uniquely flexible for skin applications. The standalone vial lists at $80. Avoid GHK-Cu if you have a copper allergy; it is otherwise well tolerated.

→ Injectable and topical compared: GHK-Cu protocol guide | Topical formulation specifics: topical GHK-Cu guide

6. The post-surgical protocol

The most common reason patients ask about wound-healing peptides is recovery from a planned procedure: orthopedic surgery, hernia repair, a tendon reconstruction, or a cosmetic procedure. The logic of a post-surgical stack is to cover the inflammation, proliferation, and remodeling phases at once.

Representative protocol (provider-directed):

• Wolverine Stack (BPC-157/TB-500): 20 units daily, Monday through Friday, to support angiogenesis and cell migration through the proliferation phase.
• GHK-Cu: 20 units (2mg), to support collagen and elastin remodeling and scar quality as the wound matures. Can be injected or, for surface wounds, applied topically.

For patients who want a single vial that already covers all four pathways, the KLOW vial combines BPC-157, TB-500, GHK-Cu, and KPV in one daily injection.

Timing is a surgeon's call. The single most important rule: clear any protocol with the surgeon who performed the procedure. Many providers wait until the acute inflammatory phase has settled and the wound is clean and closing (often the first one to two weeks) before layering peptides in. Starting too early can interfere with normal healing and post-op monitoring.

7. Chronic wound protocols

Chronic wounds, those that fail to heal in an orderly, timely sequence, are a different and more serious category than a clean surgical incision. They include venous and arterial ulcers, pressure injuries, and diabetic foot ulcers. They are typically stuck in a prolonged inflammatory phase.

The honest position. There are no completed human trials in PubMed showing wound-healing peptides resolve chronic wounds such as diabetic foot ulcers. A chronic wound is a clinical condition that demands physician-directed care: vascular assessment, infection control, debridement, offloading, and appropriate dressings. Peptides are not a substitute for any of that.

Where peptides may have a conceptual fit is as adjuncts under a clinician's supervision: KPV and TB-500 to address the stalled inflammatory phase, GHK-Cu to support remodeling, BPC-157 to support angiogenesis. But that is a hypothesis grounded in mechanism, not a proven protocol. Anyone with a non-healing wound should be under the care of a wound specialist first, and should treat peptides as a question to raise with that specialist, not a self-directed fix.

8. Burn recovery considerations

Burns are among the most demanding wounds to heal. They involve large surface areas, fluid loss, infection risk, and complex scarring, including the risk of hypertrophic scars and contractures.

The mechanistic rationale. The remodeling and anti-inflammatory profiles of GHK-Cu and KPV are conceptually relevant to burn recovery, particularly to scar quality during the long remodeling phase. GHK-Cu's documented effects on collagen, elastin, and skin remodeling are the most directly applicable.

The boundary. Significant burns are managed in burn centers and by dermatology and plastic surgery, full stop. There is no human trial base supporting peptides as a primary burn therapy, and broken skin from a burn should never be self-treated with a topical or injectable peptide. The realistic role is, at most, a provider-supervised adjunct during the later scar-remodeling phase of a minor, already healing burn, never an alternative to proper burn care.

9. Combination protocols

Because each peptide covers a different phase, the practical question is rarely which one but which combination. RxPepsDirect's prescribers can request these as pre-combined vials from Optimal Balance Pharmacy, which simplifies dosing to a single daily injection.

The progression is intuitive: start with the Wolverine Stack for general repair, step up to the triple stack when inflammation is the bottleneck, and choose KLOW when you want collagen remodeling (GHK-Cu) layered on top of the repair and anti-inflammatory pathways in a single shot. The right choice is a conversation with the prescriber, based on your wound and history.

10. Topical vs injectable for wound applications

A recurring question is whether to apply a peptide to the skin or inject it. The answer depends almost entirely on where the target tissue sits.

• Topical works for superficial skin. GHK-Cu is the peptide with real human topical evidence, and surface skin is exactly where a topical can reach its target. This makes GHK-Cu uniquely suited to surface remodeling and post-procedure skin support.
• Injectable is preferred for deep tissue. Tendon, muscle, ligament, and post-surgical repair sit below the skin, where topical peptides do not reliably penetrate. BPC-157, TB-500, and KPV are therefore delivered by subcutaneous or intramuscular injection. Injectables ship pre-reconstituted, FedEx overnight, in a reusable cooled travel case, so there is no mixing on the patient's end.
• Open wounds are off-limits for self-treatment. Neither a topical nor an injectable peptide should be applied to broken, open, or infected skin without explicit provider direction. That is a wound-care decision, not a cosmetic one.

→ A deeper comparison of the two GHK-Cu delivery routes: topical GHK-Cu guide

11. How to get a prescription for wound healing peptides

BPC-157, the Wolverine Stack (BPC-157/TB-500), the triple stack, KLOW, and GHK-Cu are all available through a licensed telehealth provider and a 503A compounding pharmacy. The process:

1. Online intake. Complete a structured health history including current medications (list antibiotics and anything taken post-surgery), allergies (including copper, which matters for GHK-Cu), cancer history, and your wound or recovery goal. No in-person clinic visit required.
2. Provider review. A licensed RxPepsDirect provider reviews your intake and, where relevant, surgical timing. If you are recovering from a procedure, the provider will expect you to have surgeon awareness of any protocol.
3. Prescription and fill. RxPepsDirect writes the prescription only. Optimal Balance Pharmacy, a 503A licensed pharmacy, fills it, ships it, and collects the medication payment. Injectable peptides arrive pre-reconstituted, FedEx overnight, in a reusable cooled travel case, with no bacteriostatic water to mix.
4. Two separate charges. RxPepsDirect bills a $39 medical visit fee for the provider review and prescription. The medication itself is billed separately by Optimal Balance Pharmacy at wholesale. Two parties, two charges.

Access: RxPepsDirect prescribers serve 28 U.S. States. Eligibility is confirmed during intake before any prescription is written.

Editorial note on evidence: claims of mechanism in this article are drawn from peer-reviewed literature indexed in PubMed and are cited inline by DOI. As stated throughout, the strongest human evidence here is for GHK-Cu in skin; BPC-157, TB-500, and KPV rest predominantly on preclinical (animal) data. This article is educational and is not medical advice. A non-healing, chronic, diabetic, or burn wound requires evaluation by a qualified clinician.